METHOD FOR PREDICTING A DRUG TRANSPORT CAPABILITY BY ABCG2 POLYMORPHISMS

• US 20080182267A1
• Filed: 03/25/2008
• Published: 07/31/2008
• Est. Priority Date: 06/17/2002
• Status: Abandoned Application

• Current Assignee: Banyu Pharmaceutical Company Limited (Merck & Co., Inc.)
• Original Assignee: Banyu Pharmaceutical Company Limited (Merck & Co., Inc.)
• Inventors: Mizuarai, Shinji, KOTANI, Hidehito
• Application Number:
  US12/055,089
• Publication Number:
  US 20080182267A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C12Q 1/6876 Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G16B 30/00 ICT specially adapted for sequence analysis involving nucleotides or amino acids

Abstract

The present invention provides polymorphisms of ABCG2 polypeptide and polynucleotide coding therefor, which is related to the intracellular accumulation of indolocarbazole compounds, as well as methods for detecting the polymorphisms, comprising collecting a sample from mammals, and determining a polymorphism of the nucleotide sequence of ABCG2 gene or a polymorphism of the amino acid sequence of ABCG2 polypeptide. In a preferred embodiment of the present invention, the polymorphism of the nucleotide sequence is one or more of single nucleotide polymorphisms at positions selected from the group consisting of 34, 376 and 421 of SEQ ID NO:1, and the polymorphism of the amino acid sequence is one or more of amino acid polymorphisms at positions consisting of 12, 126, and 141 of SEQ ID NO:2.

Claims

1-18. -18. (canceled)

19. A method for determining whether a cell carries a gene encoding an ABCG2 transporter protein with a decreased capacity to excrete compound B comprising:

performing an assay on a biological sample from a human cell and determining the nucleotide present at position 34 of SEQ ID NO;

1, wherein the presence of the nucleotide A at position 34 indicates that the cell carries a gene encoding an ABCG2 transporter protein having a decreased capacity to excrete compound B compared to a gene having the nucleotide G at position 34 of SEQ ID NO;

1;

wherein compound B is a compound of formula (I);

20. The method of claim 19, wherein the biological sample is derived from a patient suffering from cancer.

21. The method of claim 19, comprising collecting the biological sample from body fluid, skin, root of hair, mucous membrane, internal organs, placenta, or cord blood of a subject prior to performing said assay.

22. The method of claim 19, wherein said assay comprises a direct sequencing method.

23. The method of claim 19, wherein said assay comprises a Taqman method.

24. The method of claim 19, wherein said assay comprises an invader method.

25. The method of claim 19, wherein said assay comprises a mass spectrometric method, an RCA method, or a DNA chip method.

26. The method of claim 19, further comprising

testing whether said human cell has at least one other genomic polynucleotide polymorphism at a nucleotide other than position 34 of SEQ ID NO:

1.

27. The method of claim 26, wherein said at least one other genomic polynucleotide polymorphism causes amino acid substitution at position 12 of SEQ ID NO:

2.

28. The method of claim 26, wherein said at least one other genomic polynucleotide polymorphism causes amino acid termination at position 126 of SEQ ID NO:

2.

29. The method of claim 26, wherein said at least one other genomic polynucleotide polymorphism occurs at nucleotide position 376 of SEQ ID NO:

1.

30. The method of claim 26, wherein said at least one other genomic polynucleotide polymorphism occurs at nucleotide position 421 of SEQ ID NO:

1.

31. The method of claim 19, wherein said assay comprises:

hybridizing an allele-specific probe which is labeled with a fluorescent dye and a quencher to a target site, simultaneously amplifying the region including the site whereupon the hybridization probe is cleaved by 5′

-nuclease activity of Taq polymerase as the elongation reaction from the primer proceeds with PCR and detecting exponentially potentiated fluorescence of fluorescent dye which is separated from the quencher.

32. The method of claim 19, wherein said assay comprises:

hybridizing a first probe which is substantially complementary to a first site of the target nucleotide sequence, hybridizing a second probe to a second site of the target nucleotide sequence where the second probe is complementary to its 3′

-terminal side and a sequence called a flap which is non-complementary to the template to form a single strand in its 5-terminal side, invading hybridization of the second probe with the target nucleotide sequence at an SNP site by the 3-terminal of the first probe, liberating the flap from the second probe by cleavase, binding of the flap to a FRET probe which includes a sequence complementary to the flap and self-complementary sequence being labeled with both a fluorescent dye and a quencher, cleaving the part of the fluorescent dye in the FRET probe by cleavase, quantifying fluorescence of the cleaved fluorescent dye.